Indeed, treatment of prostate cancer cells with the CDK inhibitor roscovitine and the PI3K inhibitor LY294002 synergistically induces expression of the FOXO1 target gene BIM [53]. The gene discussed is FOXO1; the disease is prostate carcinoma.